This company listing is no longer active
VBI Vaccines (VBIV.Q) Stock Overview
A commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
VBIV.Q Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
VBI Vaccines Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0005 |
| 52 Week High | US$1.35 |
| 52 Week Low | US$0.00001 |
| Beta | 2.05 |
| 1 Month Change | 0% |
| 3 Month Change | -92.86% |
| 1 Year Change | -99.92% |
| 3 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
VBI Vaccines: Recent Updates Have Fortified My Long-Term Outlook
Sep 22VBI Vaccines gets up to $100M debt funding from K2 HealthVentures
Sep 15Valneva, VBI Vaccines in pact to launch Hep B vaccine in Europe
Sep 08VBI Vaccines down 10% on $300M mixed shelf offering; also ends two equity offerings
Aug 26VBI Vaccines: Recent VBI-1901 Data Supports My Bull Thesis
Jun 17Is VBI Vaccines (NASDAQ:VBIV) A Risky Investment?
Jun 09
Shareholder Returns
| VBIV.Q | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 1.6% | 3.4% |
| 1Y | -99.9% | 46.8% | 29.7% |
Return vs Industry: VBIV.Q underperformed the US Biotechs industry which returned -8.7% over the past year.
Return vs Market: VBIV.Q underperformed the US Market which returned 21.6% over the past year.
Price Volatility
| VBIV.Q volatility | |
|---|---|
| VBIV.Q Average Weekly Movement | 59.2% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: VBIV.Q's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: VBIV.Q's weekly volatility has increased from 41% to 59% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 135 | Jeff Baxter | www.vbivaccines.com |
VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers hepatitis B (HBV) vaccine under the PreHevbrio, PreHevbri, and Sci-B-Vac brand names. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma cancer vaccine immunotherapeutic candidate; VBI-1501, a prophylactic cytomegalovirus vaccine candidate; and VBI-2501 to treat Zika virus.
VBI Vaccines Inc. Fundamentals Summary
| VBIV.Q fundamental statistics | |
|---|---|
| Market cap | US$14.34k |
| Earnings (TTM) | -US$83.99m |
| Revenue (TTM) | US$9.41m |
Is VBIV.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VBIV.Q income statement (TTM) | |
|---|---|
| Revenue | US$9.41m |
| Cost of Revenue | US$11.67m |
| Gross Profit | -US$2.26m |
| Other Expenses | US$81.73m |
| Earnings | -US$83.99m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.93 |
| Gross Margin | -24.03% |
| Net Profit Margin | -892.47% |
| Debt/Equity Ratio | -891.6% |
How did VBIV.Q perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/14 02:55 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
VBI Vaccines Inc. is covered by 9 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Guyn Kim | BMO Capital Markets Equity Research |
| Kumaraguru Raja | Brookline Capital Markets |
| John Newman | Canaccord Genuity |